Trial reportBMC anesthesiology2026
Effect of different administration times of dexmedetomidine on the ED50 of sufentanil to inhibit the cardiovascular response in elderly patients with double lumen tracheal intubation: a randomized controlled trial.
Trial report in BMC anesthesiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the effect of different administration timings of dexmedetomidine (DEX) on the median effective dose (ED50) of sufentanil required to suppress the cardiovascular response during double-lumen tracheal intubation in elderly patients.
methodsNinety elderly patients (aged 65–85 years, BMI 18.5–30 kg/m2, ASA physical status I–III) scheduled for elective thoracic surgery were randomized into three groups: the Control group (induction initiated following a 10-min intravenous infusion of saline), the DEX1 group (DEX 0.6 μg/kg infused over 10 min before induction), and the DEX2 group (induction initiated 20 min after completion of a 10-min intravenous infusion of DEX at a dose of 0.6 μg/kg). Anesthesia induction was initiated with intravenous sufentanil starting at 0.5 μg/kg, and subsequent doses were determined using the Dixon up-and-down sequential method with a dose ratio of 1:1.1 between adjacent dose levels. Tracheal intubation was performed 5 min after sufentanil administration according to the predefined protocol, and the infusion-to-intubation interval was predefined according to group allocation. Sequential allocation continued until at least eight crossover pairs were obtained. Patient characteristics, hemodynamic variables, Surgical Pleth Index (SPI), and adverse events were recorded from study drug administration to 5 min after intubation.
resultsFinal analysis included 87 patients (Control: n = 30, DEX1: n = 28, DEX2: n = 29). The ED50 of sufentanil was 0.675 μg/kg (95% CI: 0.634–0.732 μg/kg) in the Control group, 0.507 μg/kg (95% CI: 0.474–0.540 μg/kg) in the DEX1 group, and 0.396 μg/kg (95% CI: 0.330–0.440 μg/kg) in the DEX2 group, corresponding to relative reductions of 24.9% and 41.3%, respectively.
conclusionPremedication with dexmedetomidine reduced the ED50 of sufentanil required to suppress the cardiovascular response to double-lumen tracheal intubation in elderly patients, with earlier administration producing a greater opioid-sparing effect. Administration of DEX 30 min before anesthesia induction resulted in the lowest sufentanil requirement.
trial registrationThis study was registered at the China Clinical Trial Registration Center (ChiCTR2400083508, April 26, 2024).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.